Edition:
United States

Intellipharmaceutics International Inc (IPCI.OQ)

IPCI.OQ on NASDAQ Stock Exchange Capital Market

0.92USD
22 Nov 2017
Change (% chg)

$0.02 (+2.08%)
Prev Close
$0.90
Open
$0.92
Day's High
$0.92
Day's Low
$0.90
Volume
23,058
Avg. Vol
57,333
52-wk High
$3.34
52-wk Low
$0.82

Chart for

About

Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of... (more)

Overall

Beta: 1.04
Market Cap(Mil.): $30.97
Shares Outstanding(Mil.): 34.70
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.56 15.47
EPS (TTM): -- -- --
ROI: -- 15.17 11.81
ROE: -- 16.58 15.76

BRIEF-Intellipharmaceutics announces US$4 mln registered direct offering

* Intellipharmaceutics announces US$4 million registered direct offering

Oct 11 2017

BRIEF-Intellipharmaceutics- Q3 loss per share $0.08

* Intellipharmaceutics International Inc - ‍ expects revenue from generic Seroquel XR to increase going forward​ Source text for Eikon: Further company coverage:

Oct 10 2017

FDA declines to approve Intellipharma's opioid painkiller

Intellipharmaceutics International Inc, said on Monday the U.S. Food and Drug Administration (FDA) declined to approve its opioid painkiller in its current form, asking for more proof of the drug's ability to prevent abuse.

Sep 25 2017

FDA declines to approve Intellipharma's opioid painkiller

Intellipharmaceutics International Inc, said on Monday the U.S. Food and Drug Administration (FDA) declined to approve its opioid painkiller in its current form, asking for more proof of the drug's ability to prevent abuse.

Sep 25 2017

UPDATE 1-FDA declines to approve Intellipharma's opioid painkiller

Sept 25Intellipharmaceutics International Inc said on Monday the U.S. Food and Drug Administration (FDA) declined to approve its long-acting opioid painkiller in its current form, backing its independent advisory panel that had raised concerns over the drug's abuse-deterrence capabilities.

Sep 25 2017

BRIEF-Intellipharmaceutics receives complete response letter from FDA for Rexista NDA

* Intellipharmaceutics receives complete response letter from the FDA for rexista™ NDA

Sep 25 2017

FDA declines to approve Intellipharma's opioid painkiller

Sept 25Intellipharmaceutics International Inc said on Monday that the U.S. Food and Drug Administration declined to approve its long-acting opioid painkiller in its current form, backing its independent advisory panel that had raised concerns over the drug's abuse-deterrence capabilities.

Sep 25 2017

BRIEF-Intellipharmaceutics provides operational update on its Rexista(TM) program

* Currently anticipate Rexista program​ study will take nine months from commencement to complete

Sep 05 2017

Fitch Affirms Brinker's IDR at 'BB+' IDR; Outlook Revised to Negative

(The following statement was released by the rating agency) CHICAGO, August 17 (Fitch) Fitch Ratings has affirmed Brinker, International, Inc.'s (Brinker) Issuer Default Rating (IDR) at 'BB+' and revised its Rating Outlook to Negative from Stable. Brinker's ratings reflect its moderately high leverage, meaningful free cash flow, and the position of Chili's Grill & Bar (Chili's) as one of the largest U.S. casual dining chains in the U.S. The company's ratings consider secular challenges in the ca

Aug 17 2017

BRIEF-Intellipharmaceutics announces resignation of CFO

* Intellipharmaceutics announces resignation of chief financial officer

Aug 08 2017

Competitors

  Price Chg
Merck & Co., Inc. (MRK.N) $54.37 +0.10
Novartis AG (NOVN.S) CHF83.60 --
Johnson & Johnson (JNJ.N) $137.29 -1.05
Pfizer Inc. (PFE.N) $35.43 -0.11

Earnings vs. Estimates